Patents Assigned to Ganymed Pharmaceuticals, AG
  • Patent number: 10414824
    Abstract: The present technology relates to the identification of genetic products expressed in association with tumors and to coding nucleic acids for the expressed products. An embodiment of the present technology also relates to the therapy and diagnosis of disease in which the genetic products are aberrantly expressed in association with tumors, proteins, polypeptides and peptides which are expressed in association with tumors, and to the nucleic acids coding for the polypeptides, peptides and proteins.
    Type: Grant
    Filed: July 14, 2017
    Date of Patent: September 17, 2019
    Assignee: GANYMED PHARMACEUTICALS AG
    Inventors: Ugur Sahin, Özlem Türeci, Michael Koslowski
  • Patent number: 10233253
    Abstract: The present invention provides antibodies useful as therapeutics for treating and/or preventing diseases associated with cells expressing CLDN6, including tumor-related diseases such as ovarian cancer, lung cancer, gastric cancer, breast cancer, hepatic cancer, pancreatic cancer, skin cancer, malignant melanoma, head and neck cancer, sarcoma, bile duct cancer, cancer of the urinary bladder, kidney cancer, colon cancer, placental choriocarcinoma, cervical cancer, testicular cancer, and uterine cancer.
    Type: Grant
    Filed: March 21, 2016
    Date of Patent: March 19, 2019
    Assignees: GANYMED PHARMACEUTICALS AG, JOHANNES GUTENBERG-UNIVERSITÄT MAINZ
    Inventors: Ugur Sahin, Ozlem Tureci, Michael Koslowski, Korden Walter, Stefan Woll, Maria Kreuzberg, Bernd Hubner, Michael Erdeljan, Michael Weichel
  • Patent number: 10125196
    Abstract: The present invention provides antibodies useful as therapeutics for treating and/or preventing diseases associated with cells expressing GT468, including tumor-related diseases such as breast cancer, lung cancer, gastric cancer, ovarian cancer, and hepatocellular cancer.
    Type: Grant
    Filed: September 6, 2016
    Date of Patent: November 13, 2018
    Assignees: GANYMED PHARMACEUTICALS AG, JOHANNES GUTENBERG-UNIVERSITÄT MAINZ
    Inventors: Ugur Sahin, Michael Koslowski, Özlem Türeci
  • Patent number: 10093736
    Abstract: The present invention provides binding agents that contain a binding domain that is specific for CD3 allowing binding to T cells and a binding domain that is specific for a tumor-associated claudin molecule and methods of using these binding agents or nucleic acids encoding therefor for treating cancer.
    Type: Grant
    Filed: November 12, 2013
    Date of Patent: October 9, 2018
    Assignees: BIONTECH AG, TRON GGMBH, UNIVERSITATSMEDIZIN DER JOHANNES GUTENBERG-UNIVERSITAT MAINZ, GANYMED PHARMACEUTICALS AG
    Inventors: Ugur Sahin, Ozlem Tureci, Christiane Stadler, Julia Holland, Hayat Bahr-Mahmud, Tim Beissert, Laura Plum, Fabrice Le Gall, Arne Jendretzki, Markus Fiedler
  • Patent number: 10053512
    Abstract: The invention relates to antibodies directed against an epitope located within the C-terminal portion of CLDN18.2 which are useful, for example, in diagnosing cancer and/or in determining whether cancer cells express CLDN18.2.
    Type: Grant
    Filed: August 3, 2016
    Date of Patent: August 21, 2018
    Assignees: GANYMED PHARMACEUTICALS AG, TRON—TRANSLATIONALE ONKOLOGIE AN DER UNIVERSITATSMEDIZIN DER JOHANNES GUTENBERG—UNIVERSITAT MAINZ GEMEINNUTZIGE GMBH
    Inventors: Ugur Sahin, Ozlem Tureci, Rita Mitnacht-Kraus, Stefan Woll
  • Patent number: 10036753
    Abstract: The invention relates to identifying tumor-associated genetic products and encoding nucleic acids thereof. A therapy and diagnosis of diseases in which the tumor-associated genetic products are aberrantly expressed, proteins, polypeptides and peptides which are expressed in association with tumor and the encoding nucleic acids for said proteins, polypeptides and peptides are also disclosed.
    Type: Grant
    Filed: June 19, 2015
    Date of Patent: July 31, 2018
    Assignee: GANYMED PHARMACEUTICALS AG
    Inventors: Ugur Sahin, Özlem Türeci, Michael Koslowski, Gerd Helftenbein, Dirk Usener, Volker Schlüter
  • Patent number: 10022444
    Abstract: The present invention provides a combination therapy for effectively treating and/or preventing diseases associated with cells expressing CLDN18.2, including cancer diseases such as gastric cancer, esophageal cancer, pancreatic cancer, lung cancer, ovarian cancer, colon cancer, hepatic cancer, head-neck cancer, and cancer of the gallbladder and metastases thereof.
    Type: Grant
    Filed: August 8, 2016
    Date of Patent: July 17, 2018
    Assignees: GANYMED PHARMACEUTICALS AG, TRON—TRANSLATIONALE ONKOLOGIE AN DER UNIVERSITATSMEDIZIN DER JOHANNES GUTENBERG UNIVERSITAT MAINZ GEMEINNUTZIGE GMBH
    Inventors: Ugur Sahin, Ozlem Tureci, Rita Mitnacht-Kraus, Stefan Denis Jacobs, Magdalena Jadwiga Utsch, Cornelia Adriana Maria Heinz, Christiane Regina Stadler
  • Patent number: 9932401
    Abstract: The present invention provides antibodies useful as therapeutics for treating and/or preventing diseases associated with cells expressing Claudin-6 (CLDN6), including tumor-related diseases such as ovarian cancer, lung cancer, gastric cancer, breast cancer, hepatic cancer, pancreatic cancer, skin cancer, malignant melanoma, head and neck cancer, sarcoma, bile duct cancer, cancer of the urinary bladder, kidney cancer, colon cancer, placental choriocarcinoma, cervical cancer, testicular cancer, and uterine cancer.
    Type: Grant
    Filed: April 20, 2016
    Date of Patent: April 3, 2018
    Assignees: Ganymed Pharmaceuticals AG, Johannes Gutenberg-Universitat Mainz
    Inventors: Ugur Sahin, Özlem Türeci, Michael Koslowski, Korden Walter, Stefan Woll, Maria Kreuzberg, Bernd Hubner, Michael Erdeljan
  • Patent number: 9919036
    Abstract: The invention relates to genetic products the expression of which is associated with cancer diseases. The invention also relates to the therapy and diagnosis of diseases in which the genetic products are expressed or aberrantly expressed, in particular cancer diseases.
    Type: Grant
    Filed: January 27, 2015
    Date of Patent: March 20, 2018
    Assignees: GANYMED PHARMACEUTICALS AG, JOHANNES GUTENBERG-UNIVERSITAT MAINZ
    Inventors: Ugur Sahin, Ozlem Tureci, Michael Koslowski, Dirk Usener
  • Patent number: 9902778
    Abstract: The invention relates to the treatment and/or prevention of tumor diseases associated with cells expressing CLDN6, in particular cancer and cancer metastasis using antibodies which bind to CLDN6. The present application demonstrates that the binding of antibodies to CLDN6 on the surface of tumor cells is sufficient to inhibit growth of the tumor and to prolong survival and extend the lifespan of tumor patients. Furthermore, binding of antibodies to CLDN6 is efficient in inhibiting growth of CLDN6 positive germ cell tumors such as teratocarcinomas or embryonal carcinomas, in particular germ cell tumors of the testis.
    Type: Grant
    Filed: July 8, 2016
    Date of Patent: February 27, 2018
    Assignees: Ganymed Pharmaceuticals AG, Johannes Gutenberg-Universitat Mainz
    Inventors: Ugur Sahin, Ozlem Tureci, Michael Koslowski, Korden Walter, Maria Kreuzberg, Sylvia Luxen
  • Patent number: 9809815
    Abstract: The present invention relates to the identification of nucleic acid and amino acid sequences that are characteristic of tumor tissues such as ovarian tumor and lung tumor tissues and which represent targets for therapy or diagnosis of tumor diseases in a subject.
    Type: Grant
    Filed: February 19, 2010
    Date of Patent: November 7, 2017
    Assignees: GANYMED PHARMACEUTICALS AG, JOHANNES GUTENBERG-UNIVERSITAT MAINZ
    Inventors: Ugur Sahin, Özlem Türeci, Michael Koslowski, Gerd Helftenbein, Korden Walter, Stefan Wöll, Gabriela-Elena Oprea
  • Patent number: 9775785
    Abstract: According to the invention, gene products expressed in a tumor-associated manner and the nucleic acids coding therefor were identified. The invention relates to the therapy and diagnosis of diseases wherein said gene products expressed in a tumor-associated manner are aberrantly expressed. The invention also relates to proteins, polypeptides and peptides which are expressed in a tumor associated manner and to nucleic acids coding therefor.
    Type: Grant
    Filed: April 1, 2015
    Date of Patent: October 3, 2017
    Assignee: GANYMED PHARMACEUTICALS AG
    Inventors: Ozlem Tureci, Ugur Sahin, Michael Koslowski, Stephan Fritz, Harald-Gerhard Geppert
  • Patent number: 9770487
    Abstract: The present invention provides a combination therapy for effectively treating and/or preventing diseases associated with cells expressing CLDN18.2, including cancer diseases such as pancreatic cancer and metastases thereof.
    Type: Grant
    Filed: February 18, 2014
    Date of Patent: September 26, 2017
    Assignees: Ganymed Pharmaceuticals AG, TRON—Translationale Onkologie an der Universitatsmedizin der Johannes Gutenberg-Universitat Mainz gGmbH
    Inventors: Ugur Sahin, Ozlem Tureci, Rita Mitnacht-Kraus, Stefan Woll, Stefan Jacobs, Cornelia Heinz
  • Patent number: 9751934
    Abstract: The present invention provides antibodies useful as therapeutics for treating and/or preventing diseases associated with cells expressing CLD18, including tumor-related diseases such as gastric cancer, esophageal cancer, pancreatic cancer, lung cancer, ovarian cancer, colon cancer, hepatic cancer, head-neck cancer, and cancer of the gallbladder.
    Type: Grant
    Filed: March 18, 2015
    Date of Patent: September 5, 2017
    Assignees: Ganymed Pharmaceuticals AG, Johannes Gutenberg-Universitat Mainz
    Inventors: Ugur Sahin, Özlem Türeci, Dirk Usener, Stefan Fritz, Christoph Uherek, Gunda Brandenburg, Harald-Gerhard Geppert, Anja Kristina Schröder, Phillippe Thiel
  • Patent number: 9733251
    Abstract: The present invention provides agents with tumor-inhibiting activity, and which are selective for cells expressing or abnormally expressing a tumor-associated antigen. Said tumor-associated antigen has a nucleotide sequence selected from the group consisting of: (a) a nucleotide sequence selected from the specific sequences set forth herein, or a 6-50 contiguous nucleotide residue portion thereof; (b) a nucleotide sequence of a nucleic acid which hybridizes with a nucleic acid having the nucleotide sequence of (a) under stringent conditions; (c) a nucleotide sequence which is degenerate with respect to the nucleotide sequence of (a) or (b); and (d) a nucleotide sequence which is complementary to the nucleotide sequence of (a), (b) or (c). Pharmaceutical compositions and kits comprising the agents are also provided, as well as methods treating, diagnosing or monitoring a disease characterized by expression or abnormal expression of the tumor-associated antigen.
    Type: Grant
    Filed: September 9, 2015
    Date of Patent: August 15, 2017
    Assignee: Ganymed Pharmaceuticals, AG
    Inventors: Özlem Türeci, Ugur Sahin, Gerd Helftenbein, Volker Schlüter
  • Patent number: 9718886
    Abstract: The invention relates to the treatment and/or prevention of tumor diseases associated with cells expressing CLDN6, in particular cancer and cancer metastasis using antibodies which bind to CLDN6. The present application demonstrates that the binding of antibodies to CLDN6 on the surface of tumor cells is sufficient to inhibit growth of the tumor and to prolong survival and extend the lifespan of tumor patients. Furthermore, binding of antibodies to CLDN6 is efficient in inhibiting growth of CLDN6 positive germ cell tumors such as teratocarcinomas or embryonal carcinomas, in particular germ cell tumors of the testis.
    Type: Grant
    Filed: July 4, 2011
    Date of Patent: August 1, 2017
    Assignees: GANYMED PHARMACEUTICALS AG, JOHANNES GUTENBERG-UNIVERSITAT MAINZ
    Inventors: Ugur Sahin, Ozlem Tureci, Michael Koslowski, Korden Walter, Maria Kreuzberg, Sylvia Luxen
  • Patent number: 9637548
    Abstract: The present invention relates to the identification of nucleic acid and amino acid sequences that are characteristic of colorectal, in particular colonic, and gastric tumor tissues and colorectal, in particular colonic, and gastric tissues, and which represent targets for therapy or diagnosis of such tumor diseases in a subject.
    Type: Grant
    Filed: February 18, 2010
    Date of Patent: May 2, 2017
    Assignees: GANYMED PHARMACEUTICALS AG, JOHANNES GUTENBERG-UNIVERSITAT MAINZ
    Inventors: Ugur Sahin, Özlem Türeci, Michael Koslowski
  • Patent number: 9512232
    Abstract: The invention relates to antibodies directed against an epitope located within the C-terminal portion of CLDN18.2 which are useful, for example, in diagnosing cancer and/or in determining whether cancer cells express CLDN18.2.
    Type: Grant
    Filed: May 6, 2013
    Date of Patent: December 6, 2016
    Assignees: GANYMED PHARMACEUTICALS AG, TRON—Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg-Universität Mainz gemeinnützige GmbH
    Inventors: Ugur Sahin, Özlem Türeci, Rita Mitnacht-Kraus, Stefan Wöll
  • Patent number: 9499609
    Abstract: The present invention provides antibodies useful as therapeutics for treating and/or preventing diseases associated with cells expressing CLD1 8, including tumor-related diseases such as gastric cancer, esophageal cancer, pancreatic cancer, lung cancer, ovarian cancer, colon cancer, hepatic cancer, head-neck cancer, and cancer of the gallbladder.
    Type: Grant
    Filed: November 29, 2011
    Date of Patent: November 22, 2016
    Assignees: GANYMED PHARMACEUTICALS AG, JOHANNES GUTENBERG-UNIVERSITAT MAINZ
    Inventors: Ugur Sahin, Özlem Türeci, Dirk Usener, Stefan Fritz, Christoph Uherek, Gunda Brandenburg, Harald-Gerhard Geppert, Anja Kristina Schröder, Phillippe Thiel
  • Patent number: 9487584
    Abstract: The present invention provides antibodies useful as therapeutics for treating and/or preventing diseases associated with cells expressing Claudin-6 (CLDN6), including tumor-related diseases such as ovarian cancer, lung cancer, gastric cancer, breast cancer, hepatic cancer, pancreatic cancer, skin cancer, malignant melanoma, head and neck cancer, sarcoma, bile duct cancer, cancer of the urinary bladder, kidney cancer, colon cancer, placental choriocarcinoma, cervical cancer, testicular cancer, and uterine cancer.
    Type: Grant
    Filed: November 11, 2010
    Date of Patent: November 8, 2016
    Assignees: GANYMED PHARMACEUTICALS AG, JOHANNES GUTENBERG-UNIVERSITAT MAINZ
    Inventors: Ugur Sahin, Ozlem Tureci, Michael Koslowski, Korden Walter, Stefan Woll, Maria Kreuzberg, Bernd Hubner, Michael Erdeljan